TY - JOUR
T1 - Associations between acute and chronic graft-versus-host disease
AU - Tamaki, Masaharu
AU - Akahoshi, Yu
AU - Inamoto, Yoshihiro
AU - Morita, Kaoru
AU - Uchida, Naoyuki
AU - Doki, Noriko
AU - Tanaka, Masatsugu
AU - Nishida, Tetsuya
AU - Ohigashi, Hiroyuki
AU - Nakamae, Hirohisa
AU - Onizuka, Makoto
AU - Katayama, Yuta
AU - Matsuoka, Ken Ichi
AU - Sawa, Masashi
AU - Ishimaru, Fumihiko
AU - Kanda, Yoshinobu
AU - Fukuda, Takahiro
AU - Atsuta, Yoshiko
AU - Terakura, Seitaro
AU - Kanda, Junya
N1 - Publisher Copyright:
© 2024 by The American Society of Hematology.
PY - 2024/8/27
Y1 - 2024/8/27
N2 - Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Although various risk factors for chronic GVHD have been reported, limited data are available regarding the impact of acute GVHD on chronic GVHD. We examined the association between acute and chronic GVHD using a Japanese registry data set. The landmark point was set at day 100 after allo-HCT, and patients who died or relapsed before the landmark point were excluded. In total, 14 618 and 6135 patients who underwent allo-HCT with bone marrow or peripheral blood (BM/PB) and with umbilical cord blood (UCB), respectively, were analyzed. In the BM/PB cohort, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P < .001]; grade 1 vs 2 [HR, 1.41; 95% CI, 1.28-1.56; P < .001]), but the risk was similar between acute GVHD grade 2 and grade 3 to 4 (HR, 1.02; 95% CI, 0.91-1.15; P = 1.0). These findings were confirmed in the UCB cohort. We further observed that the risk for severe chronic GVHD increased with each increment in the grade of acute GVHD, even between acute GVHD grade 2 and grade 3 to (grade 2 vs 3-4: HR, 1.70; 95% CI, 1.12-2.58; P = .025). In conclusion, the preceding profiles of acute GVHD should help to stratify the risk for chronic GVHD and its severity, which might be useful for the development of risk-adopted preemptive strategies for chronic GVHD.
AB - Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Although various risk factors for chronic GVHD have been reported, limited data are available regarding the impact of acute GVHD on chronic GVHD. We examined the association between acute and chronic GVHD using a Japanese registry data set. The landmark point was set at day 100 after allo-HCT, and patients who died or relapsed before the landmark point were excluded. In total, 14 618 and 6135 patients who underwent allo-HCT with bone marrow or peripheral blood (BM/PB) and with umbilical cord blood (UCB), respectively, were analyzed. In the BM/PB cohort, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P < .001]; grade 1 vs 2 [HR, 1.41; 95% CI, 1.28-1.56; P < .001]), but the risk was similar between acute GVHD grade 2 and grade 3 to 4 (HR, 1.02; 95% CI, 0.91-1.15; P = 1.0). These findings were confirmed in the UCB cohort. We further observed that the risk for severe chronic GVHD increased with each increment in the grade of acute GVHD, even between acute GVHD grade 2 and grade 3 to (grade 2 vs 3-4: HR, 1.70; 95% CI, 1.12-2.58; P = .025). In conclusion, the preceding profiles of acute GVHD should help to stratify the risk for chronic GVHD and its severity, which might be useful for the development of risk-adopted preemptive strategies for chronic GVHD.
UR - http://www.scopus.com/inward/record.url?scp=85202995696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85202995696&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2024013442
DO - 10.1182/bloodadvances.2024013442
M3 - Article
C2 - 38985337
AN - SCOPUS:85202995696
SN - 2473-9529
VL - 8
SP - 4250
EP - 4261
JO - Blood Advances
JF - Blood Advances
IS - 16
ER -